PaSA (Purchasing and Supply Agency) supports products on trial basis:
This article was originally published in Clinica
Executive Summary
The UK NHS Purchasing and Supply Agency (PaSA) has agreed to support the policy of the British Healthcare Trades Association (BHTA) to allow hospital trusts to receive products for a trial period of up to 14 days. The association, which covers the rehabilitation sector, is recommending that normal commercial rates should be charged after 14 days have expired. PaSA agrees that this policy is reasonable and should not discourage new, and especially smaller, suppliers from entering the market.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.